Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry

Overview of attention for article published in Digestive and Liver Disease, August 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 2,097)
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 1 news outlet

twitter: 33 X users

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 28 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Ustekinumab, Vedolizumab May Effectively Prevent Postoperative Recurrence in Crohn Disease

Clinical Advisor, 06 Sep 2022

Ustekinumab and vedolizumab are efficacious for preventing postoperative recurrence among patients with Crohn disease (CD) who…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.